In fact, the combination of chidamide and decitabine improves the KMT2D-PU.1 transcription factor interaction, which inactivates the MAPK pathway [161], constitutively activated in T-cell lymphoma [162]. The gene discussed is KMT2D; the disease is T-cell non-Hodgkin lymphoma.